There were 302 press releases posted in the last 24 hours and 357,556 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image